Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+ cells

Leukemia

Volumn 27, Issue 11, 2013, Pages 2177-2186

  Wei, Y ^a   Chen, R ^b   Dimicoli, S ^a   Bueso Ramos, C ^a   Neuberg, D ^c   Pierce, S ^a   Wang, H ^b   Yang, H ^a   Jia, Y ^a   Zheng, H ^a   Fang, Z ^a   Nguyen, M ^a   Ganan Gomez, I ^a,d   Ebert, B ^e   Levine, R ^f   Kantarjian, H ^a   Garcia Manero, G ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d UNIVERSITY OF ALCALÁ   (Spain)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

CHIP Seq; H3K4me3; innate immunity; JMJD3; myelodysplastic syndromes

Indexed keywords

HISTONE 3 LYSINE 4; HISTONE DEMETHYLASE; HISTONE H3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JUMONJI DOMAIN CONTAINING 3; UNCLASSIFIED DRUG;

ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; GENE IDENTIFICATION; GENE MAPPING; GENE OVEREXPRESSION; GENE SEQUENCE; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; INNATE IMMUNITY; MYELODYSPLASTIC SYNDROME; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

EID: 84887322071     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.91     Document Type: Article

References (60)

1. Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med. 2009; 361: 1872-1885.
2. Garcia-Manero G, Fenaux P. Hypomethylating agents and other novel strategies in myelodysplastic syndromes. J Clin Oncol 2011; 29: 516-523.
3. Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Perez WS, Anasetti C et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004; 104: 579-585. (Pubitemid 38900045)
4. Slape C, Lin YW, Hartung H, Zhang Z, Wolff L, Aplan PD. NUP98-HOX translocations lead to myelodysplastic syndrome in mice and men. J Natl Cancer Inst Monogr 2008 64-68.
5. Schanz J, Steidl C, Fonatsch C, Pfeilstocker M, Nosslinger T, Tuechler H et al. Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. J Clin Oncol 2011; 29: 1963-1970.
6. Bejar R, Levine R, Ebert BL. Unraveling the molecular pathophysiology of myelodysplastic syndromes. J Clin Oncol 2011; 29: 504-515.
7. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011; 364: 2496-2506.
8. Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011; 365: 1384-1395.
9. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z et al. High-resolution profiling of histone methylations in the human genome. Cell 2007; 129: 823-837. (Pubitemid 46802390)
10. Orford K, Kharchenko P, Lai W, Dao MC, Worhunsky DJ, Ferro A et al. Differential H3K4 methylation identifies developmentally poised hematopoietic genes. Dev Cell 2008; 14: 798-809. (Pubitemid 351622618)
11. Jepsen K, Solum D, Zhou T, McEvilly RJ, Kim HJ, Glass CK et al. SMRT-mediated repression of an H3K27 demethylase in progression from neural stem cell to neuron. Nature 2007; 450: 415-419. (Pubitemid 350126746)
12. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009; 25: 1754-1760.
13. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE et al. Modelbased analysis of ChIP-Seq (MACS). Genome Biol 2008; 9: R137.
14. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010; 20: 1297-1303.
15. Bueso-Ramos CE, Rocha FC, Shishodia S, Medeiros LJ, Kantarjian HM, Vadhan-Raj S et al. Expression of constitutively active nuclear-kappa B RelA transcription factor in blasts of acute myeloid leukemia. Hum Pathol 2004; 35: 246-253. (Pubitemid 38240909)
16. Agger K, Cloos PA, Rudkjaer L, Williams K, Andersen G, Christensen J et al. The H3K27me3 demethylase JMJD3 contributes to the activation of the INK4A-ARF locus in response to oncogene-and stress-induced senescence. Genes Dev 2009; 23: 1171-1176.
17. Braun T, Carvalho G, Coquelle A, Vozenin MC, Lepelley P, Hirsch F et al. NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. Blood 2006; 107: 1156-1165. (Pubitemid 43156318)
18. Sakurai H, Chiba H, Miyoshi H, Sugita T, Toriumi W. IkappaB kinases phosphorylate NF-kappaB p65 subunit on serine 536 in the transactivation domain. J Biol Chem 1999; 274: 30353-30356.
19. De Santa F, Totaro MG, Prosperini E, Notarbartolo S, Testa G, Natoli G. The histone H3 lysine-27 demethylase Jmjd3 links inflammation to inhibition of polycombmediated gene silencing. Cell 2007; 130: 1083-1094. (Pubitemid 47410272)
20. Sen GL, Webster DE, Barragan DI, Chang HY, Khavari PA. Control of differentiation in a self-renewing mammalian tissue by the histone demethylase JMJD3. Genes Dev 2008; 22: 1865-1870. (Pubitemid 352008635)
21. Cibull TL, Thomas AB, O'Malley DP, Billings SD. Myeloid leukemia cutis: a histologic and immunohistochemical review. J Cutan Pathol 2008; 35: 180-185.
22. De Santa F, Narang V, Yap ZH, Tusi BK, Burgold T, Austenaa L et al. Jmjd3 contributes to the control of gene expression in LPS-activated macrophages. EMBO J 2009; 28: 3341-3352.
23. Frisan E, Vandekerckhove J, de Thonel A, Pierre-Eugene C, Sternberg A, Arlet JB et al. Defective nuclear localization of Hsp70 is associated with dyserythropoiesis and GATA-1 cleavage in myelodysplastic syndromes. Blood 2012; 119: 1532-1542.
24. Sawada K, Sato N, Notoya A, Tarumi T, Hirayama S, Takano H et al. Proliferation and differentiation of myelodysplastic CD34\+ cells: phenotypic subpopulations of marrow CD34\+ cells. Blood 1995; 85: 194-202.
25. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088. (Pubitemid 27132124)
26. Vastenhouw NL, Schier AF. Bivalent histone modifications in early embryogenesis. Curr Opin Cell Biol 2012; 24: 374-386.
27. Pellagatti A, Cazzola M, Giagounidis A, Perry J, Malcovati L, Della Porta MG et al. Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells. Leukemia 2010; 24: 756-764.
28. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010; 140: 805-820.
29. Starczynowski DT, Kuchenbauer F, Argiropoulos B, Sung S, Morin R, Muranyi A et al. Identification of miR-145 and miR-146a as mediators of the 5q-syndrome phenotype. Nat Med 2010; 16: 49-58.
30. Esplin BL, Shimazu T, Welner RS, Garrett KP, Nie L, Zhang Q et al. Chronic exposure to a TLR ligand injures hematopoietic stem cells. J Immunol 2011; 186: 5367-5375.
31. Nagai Y, Garrett KP, Ohta S, Bahrun U, Kouro T, Akira S et al. Toll-like receptors on hematopoietic progenitor cells stimulate innate immune system replenishment. Immunity 2006; 24: 801-812. (Pubitemid 43867369)
32. Chen S, Ma J, Wu F, Xiong LJ, Ma H, Xu W et al. The histone H3 Lys 27 demethylase JMJD3 regulates gene expression by impacting transcriptional elongation. Genes Dev 2012; 26: 1364-1375.
33. Miller SA, Mohn SE, Weinmann AS. Jmjd3 and UTX play a demethylase-independent role in chromatin remodeling to regulate T-box family memberdependent gene expression. Mol Cell 2010; 40: 594-605.
34. Kruidenier L, Chung CW, Cheng Z, Liddle J, Che K, Joberty G et al. A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature 2012; 488: 404-408.
35. Rice JC, Allis CD. Code of silence. Nature 2001; 414: 258-261. (Pubitemid 33097787)
36. Bernstein BE, Mikkelsen TS, Xie X, Kamal M, Huebert DJ, Cuff J et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 2006; 125: 315-326.
37. Raaijmakers MH, Mukherjee S, Guo S, Zhang S, Kobayashi T, Schoonmaker JA et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 2010; 464: 852-857.
38. Lopez-Villar O, Garcia JL, Sanchez-Guijo FM, Robledo C, Villaron EM, Hernandez-Campo P et al. Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5qsyndrome. Leukemia 2009; 23: 664-672.
39. Kinet JP. The high-affinity IgE receptor (Fc epsilon RI): from physiology to pathology. Annu Rev Immunol 1999; 17: 931-972.
40. Fillon S, Soulis K, Rajasekaran S, Benedict-Hamilton H, Radin JN, Orihuela CJ et al. Platelet-activating factor receptor and innate immunity: uptake of gram-positive bacterial cell wall into host cells and cell-specific pathophysiology. J Immunol 2006; 177: 6182-6191. (Pubitemid 44628836)
41. Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, van Zoelen MA et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med 2007; 13: 1042-1049. (Pubitemid 47517513)
42. Bave U, Magnusson M, Eloranta ML, Perers A, Alm GV, Ronnblom L. Fc gamma RIIa is expressed on natural IFN-alpha-producing cells (plasmacytoid dendritic cells) and is required for the IFN-alpha production induced by apoptotic cells combined with lupus IgG. J Immunol 2003; 171: 3296-3302. (Pubitemid 37093557)
43. Lowell CA, Soriano P, Varmus HE. Functional overlap in the src gene family: inactivation of hck and fgr impairs natural immunity. Genes Dev 1994; 8: 387-398. (Pubitemid 24071180)
44. Eklund EA, Kakar R. Recruitment of CREB-binding protein by PU.1, IFN-regulatory factor-1, and the IFN consensus sequence-binding protein is necessary for IFN-gamma-induced p67phox and gp91phox expression. J Immunol 1999; 163: 6095-6105.
45. Brown MH, Boles K, van der Merwe PA, Kumar V, Mathew PA, Barclay AN. 2B4, the natural killer and T cell immunoglobulin superfamily surface protein, is a ligand for CD48. J Exp Med 1998; 188: 2083-2090. (Pubitemid 28562525)
46. Godaly G, Hang L, Frendeus B, Svanborg C. Transepithelial neutrophil migration is CXCR1 dependent in vitro and is defective in IL-8 receptor knockout mice. J Immunol 2000; 165: 5287-5294.
47. Gomez MA, Li S, Tremblay ML, Olivier M. NRAMP-1 expression modulates proteintyrosine phosphatase activity in macrophages: impact on host cell signaling and functions. J Biol Chem 2007; 282: 36190-36198.
48. Coppolino MG, Krause M, Hagendorff P, Monner DA, Trimble W, Grinstein S et al. Evidence for a molecular complex consisting of Fyb/SLAP, SLP-76, Nck, VASP and WASP that links the actin cytoskeleton to Fcgamma receptor signalling during phagocytosis. J Cell Sci 2001; 114(Pt 23): 4307-4318. (Pubitemid 33138667)
49. Matsushita M, Endo Y, Fujita T. Cutting edge: complement-activating complex of ficolin and mannose-binding lectin-associated serine protease. J Immunol 2000; 164: 2281-2284. (Pubitemid 30115453)
50. Brass AL, Huang IC, Benita Y, John SP, Krishnan MN, Feeley EM et al. The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell 2009; 139: 1243-1254.
51. Gantner BN, Simmons RM, Canavera SJ, Akira S, Underhill DM. Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2. J Exp Med 2003; 197: 1107-1117. (Pubitemid 36570066)
52. Sukumaran B, Carlyon JA, Cai JL, Berliner N, Fikrig E. Early transcriptional response of human neutrophils to Anaplasma phagocytophilum infection. Infect Immun 2005; 73: 8089-8099. (Pubitemid 41740296)
53. Gumienny TL, Brugnera E, Tosello-Trampont AC, Kinchen JM, Haney LB, Nishiwaki K et al. CED-12/ELMO, a novel member of the CrkII/Dock180/Rac pathway, is required for phagocytosis and cell migration. Cell 2001; 107: 27-41. (Pubitemid 32972035)
54. Centola M, Wood G, Frucht DM, Galon J, Aringer M, Farrell C et al. The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. Blood 2000; 95: 3223-3231. (Pubitemid 30321178)
55. Gerard NP, Hodges MK, Drazen JM, Weller PF, Gerard C. Characterization of a receptor for C5a anaphylatoxin on human eosinophils. J Biol Chem 1989; 264: 1760-1766. (Pubitemid 19051021)
56. Le Y, Gong W, Li B, Dunlop NM, Shen W, Su SB et al. Utilization of two seventransmembrane, G protein-coupled receptors, formyl peptide receptor-like 1 and formyl peptide receptor, by the synthetic hexapeptide WKYMVm for human phagocyte activation. J Immunol 1999; 163: 6777-6784.
57. Shen L, Collins JE, Schoenborn MA, Maliszewski CR. Lipopolysaccharide and cytokine augmentation of human monocyte IgA receptor expression and function. J Immunol 1994; 152: 4080-4086. (Pubitemid 24111080)
58. Tomasello E, Desmoulins PO, Chemin K, Guia S, Cremer H, Ortaldo J et al. Combined natural killer cell and dendritic cell functional deficiency in KARAP/DAP12 loss-of-function mutant mice. Immunity 2000; 13: 355-364.
59. Xu Y, Ma M, Ippolito GC, Schroeder Jr. HW, Carroll MC, Volanakis JE. Complement activation in factor D-deficient mice. Proc Natl Acad Sci USA 2001; 98: 14577-14582. (Pubitemid 33121434)
60. Jeon JW, Jung JG, Shin EC, Choi HI, Kim HY, Cho ML et al. Soluble CD93 induces differentiation of monocytes and enhances TLR responses. J Immunol 2010; 185: 4921-4927.